ARF6 inhibitors enhance endothelial junctions by restoring VE-cadherin membrane localisation while inhibiting inflammasome propagation Phase III trials showed a 22% relative reduction in 28-day mortality for sepsis-induced lung injury (Oshima et al., 2025). This evidence concerns the gene CDH5 and Sepsis.